Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 6;13:31–44. doi: 10.2147/OTT.S224062

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Wu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Dioscin inhibited tumor glycolysis in colorectal cancers by downregulating hexokinase-2. (A) The expression of hexokinase-2 in colorectal cancer tissue and paired adjacent tissue was examined by IHC staining. Left, the representative images; right, the statistics of hexokinase-2 expression. ***p<0.001 indicated a significant difference. (B) The expression of hexokinase-2 in normal colon cells and colorectal cancer cells was examined by Western blotting. (C–E) HT-29 (C), HCT-116 (D) and SW-480 (E) cells were treated with dioscin and the expression of hexokinase-2 (left), glucose consumption (middle) or lactate production (right) was measured, respectively. (F–G) Hexokinase-2 overexpression impaired dioscin-induced glycolysis inhibition. Ectopic overexpression of hexokinase-2 was performed in HCT-116 and HT-29 cells and then treated with 5 μM dioscin, the amount of glucose (F) and lactate (G) were measured as described. *p<0.05, **p<0.01, ***p<0.001 versus the control.